Get started
Work

Abstract PS1-10-26: Comparative analysis of blood- and tissue-based PIK3CA mutation detection methods in the pivotal Phase 3 INAVO120 trial of palbociclib + fulvestrant ± inavolisib in hormone receptor-positive, HER2-negative advanced breast cancer

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-ps1-10-26
Authors: S. Hilz, K. Kalinsky, D. Juric, N. Turner, K. Jhaveri, S. Im, S. Loibl, S. Loi, C. Saura, P. Schmid, E. Shaddox, N. Pantoja Galicia, C. Guo, Y. Li, W. Darbonne, R. Desai, M. Pagan, P. Karavagul, J. Aimi, S. Royer-Joo, J. Schutzmann, T. Stout, C. Song, P. Bedard, K. Hutchinson
Institutions: Genentech, Emory University, Winship Cancer Institute, Harvard University, Institute of Cancer Research, Royal Marsden Hospital, Memorial Sloan Kettering Cancer Center, Seoul National University, Goethe University Frankfurt, German Breast Group, The University of Melbourne, Peter MacCallum Cancer Centre, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Queen Mary University of London, Barts Cancer Institute, Foundation Medicine (United States), Roche (Switzerland), University Health Network, University of Toronto, Princess Margaret Cancer Centre
Language: English
Subfield: Cancer Research
Open Access status: closed
OpenAlex ID: W7129350306
Cites:
Cited by:
Related to: